ABL Bio Inc. has reached an exclusive worldwide license agreement with Sanofi to develop and commercialize the South Korean biotech’s still preclinical stage, enhanced blood-brain barrier (BBB) penetration bispecific antibody ABL301 for Parkinson’s disease and other potential indications, in a deal worth up to $1.06bn.
"This ground-breaking partnership with Sanofi proves the immense possibilities of ABL's innovative bispecific antibody technology," declared ABL CEO Sang Hoon...








